Structure Therapeutics Inc. (GPCR)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
GPCR Insider Trading Activity
GPCR Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $0 | 3 | 100 |
Related Transactions
| FMR LLC | See Remark 1 | 0 | $0 | 1 | $0 | $0 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 1 | $0 | $0 |
| Stevens Raymond C | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $0 | $0 |
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Insider Activity of Structure Therapeutics Inc.
Over the last 12 months, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of Structure Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Structure Therapeutics Inc.
| 2025-02-06 | Sale | FMR LLC | See Remark 1 | 41 – | $0 | $0 | -23.98% | |
| 2024-06-10 | Sale | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | 185,000 – | $0 | $0 | -31.33% | |
| 2024-06-03 | Sale | Lin Xichen | CHIEF SCIENTIFIC OFFICER | 35,400 – | $0 | $0 | -30.77% |
GPCR Institutional Investors: Active Positions
| Increased Positions | 94 | +54.97% | 8M | +13.67% |
| Decreased Positions | 74 | -43.27% | 9M | -14.22% |
| New Positions | 29 | New | 3M | New |
| Sold Out Positions | 24 | Sold Out | 3M | Sold Out |
| Total Postitions | 191 | +11.7% | 61M | -0.56% |
GPCR Ownership Change vs Market
Institutional Investor Ownership
| Wellington Management Group Llp | $184,908.00 | 4.53% | 7.79M | +15,843 | +0.2% | 2024-12-31 |
| Fmr Llc | $144,370.00 | 3.53% | 6.08M | -49,698 | -0.81% | 2024-12-31 |
| Janus Henderson Group Plc | $98,797.00 | 2.42% | 4.16M | +203,010 | +5.13% | 2024-12-31 |
| Capital Research Global Investors | $84,012.00 | 2.06% | 3.54M | +6,891 | +0.2% | 2024-12-31 |
| Deep Track Capital, Lp | $66,500.00 | 1.63% | 2.8M | +2M | +129.41% | 2024-12-31 |
| Driehaus Capital Management Llc | $48,863.00 | 1.2% | 2.06M | -469,020 | -18.57% | 2024-12-31 |
| Federated Hermes, Inc. | $48,592.00 | 1.19% | 2.05M | -365,642 | -15.16% | 2024-12-31 |
| Bvf Inc/Il | $42,071.00 | 1.03% | 1.77M | -467,569 | -20.88% | 2024-12-31 |
| Vestal Point Capital, Lp | $40,969.00 | 1% | 1.73M | +575,000 | +50% | 2024-12-31 |
| Capital International Investors | $38,453.00 | 0.94% | 1.62M | +103,059 | +6.8% | 2024-12-31 |